Drug Trial Radar · NCT06042725
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Actual
Start
Apr 11, 2024
Primary completion
May 28, 2026
Study completion May 29, 2027
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with lenalidomide and dexamethasone, daratumumab and dexamethasone, or daratumumab, lenalidomide, and dexamethasone in treating patients with multiple myeloma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Lenalidomide is a drug that is similar to thalidomide, and is used to treat multiple myeloma and certain types of anemia. Lenalidomide belongs to the family of drugs called angiogenesis inhibitors. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Adding venetoclax to the other drug combinations may allow control of the cancer than is possible with the current treatments.
Conditions
- Multiple Myeloma
Interventions
Biospecimen CollectionProcedure
Undergo optional collection of blood samples
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Chest RadiographyProcedure
Undergo chest x-ray
Computed TomographyProcedure
Undergo PET/CT
DaratumumabBiological
Given SC
DexamethasoneDrug
Given PO
LenalidomideDrug
Given PO
Low Dose Computed Tomography of the Whole BodyProcedure
Undergo WBLDCT
Magnetic Resonance ImagingProcedure
Undergo MRI
Positron Emission TomographyProcedure
Undergo PET/CT
VenetoclaxDrug
Given PO
X-Ray ImagingProcedure
Undergo x-rays
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicityTime frame: 28 Days (1 treatment cycle); Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.